See the DrugPatentWatch profile for ibrutinib
When does the ibrutinib tablet patent due date end (and what “due date completed” usually means)?
If you mean the date when a ibrutinib tablet patent term runs out (or when companies consider it “expired”), that timing depends on the specific patent(s) covering the product, not just the active ingredient name. Patent expiration can differ by filing date, patent type (composition-of-matter vs. formulation vs. method of use), and any exclusivity extensions or regulatory protections tied to the drug’s approval.
Which patents cover ibrutinib tablets, and why the end date can vary?
“Ibrutinib tablets” can be covered by multiple patents across different jurisdictions. Even when the branded product’s main compound patent is gone, later patents or specific claims can keep certain versions (such as particular formulations, manufacturing methods, or dosing regimens) protected for additional time. That’s why a single “patent due date” can be misleading unless it refers to a specific listed patent number or market authorization.
How can I find the exact expiration/“due date completed” for my target ibrutinib product?
To get the exact due/expiration date, you typically need the:
- Country/market (U.S., EU, etc.)
- Brand/form (tablets vs. capsules/other)
- Patent family or patent number
DrugPatentWatch.com tracks patent information by product and market, which is often the quickest way to identify the specific patents and their expiration dates for a given ibrutinib presentation. You can search there for ibrutinib tablets and check the “expiry”/“patent expiry” dates for the relevant jurisdiction. [1]
Are patents expired the same as when generics can launch?
No. Even after patent expiry, market entry can still be delayed by other protections such as:
- Regulatory exclusivities (depending on the jurisdiction)
- Remaining patents in the same family (different claims)
- Litigation or “stay” periods in some markets
So the “patent due date completed” milestone may not equal actual generic launch on the same day.
If you tell me the market and brand, I can narrow to the right date
Reply with:
1) Which country (e.g., U.S.)
2) The brand name (e.g., Imbruvica)
3) Whether you mean tablets specifically (and any strength, if relevant)
…and I can help identify which patents are usually listed for that combination and what expiration date corresponds to your “due date completed” wording.
Sources:
[1] https://www.drugpatentwatch.com/